2022-RA-1048-ESGO Circulating HPV cell-free DNA in cervical cancer

Suzana Mittelstadt, Christopher Schroeder, Olga Kelemen, Tobias Engler, Jakob Admard, Axel Gschwind, Andre Koch, Sarah Elisabeth Wörz, Ernst Oberlechner, Sascha Hoffmann, Jürgen Andress, Felix Neis (+7 others)
2022 Cervical cancer   unpublished
120 g/L and pre-brachytherapy Hb < 120 g/L was 9%, 15% and 22% respectively. The 3 year overall survival rate was 72%, 65% and 49% respectively. 52 patients (38.5%) had anaemia at presentation (Hb < 120 g/L). There was significant association between anaemia and younger age, more advanced stage and lymph node involvement. Anaemia was corrected by blood transfusion and/or ferric carboxymaltose. The pre-brachytherapy Hb level had the strongest impact on both local failure and survival. The
more » ... eatment Hb level did not have an impact on the outcomes. Conclusion Anaemia in patients with cervical cancer undergoing chemoradiation was a strong prognostic factor for local control and survival. The pre-brachytherapy Hb level had the strongest impact indicating the benefit from correcting the anaemia before treatment and maintaining the Hb level above 120 g/L during the treatment.
doi:10.1136/ijgc-2022-esgo.85 fatcat:qelniwzofrer7ndvnkxpun3ndm